TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24171516

Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation after one additional cycle of induction chemotherapy
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (three additional cycles of induction chemotherapy)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: High-risk patients in the transplantation group
Number of subjects: 370

Group type: COMPARATOR
Intervention: High-risk patients in the control group
Number of subjects: 370
Study: 21223597

Group type: EXPERIMENTAL
Intervention: Intervention group participants (n = 175)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Usual care group participants (n = 166)
Number of subjects: 341
Study: 19766757

Group type: EXPERIMENTAL
Intervention: Single-bolus intravenous administration of sodium bicarbonate (20 mEq) plus standard hydration with sodium chloride
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard hydration alone
Number of subjects: 144
Study: 17675917

Group type: EXPERIMENTAL
Intervention: Sulbutiamine + Donepezil (S + D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Donepezil + Placebo (D + P)
Number of subjects: 0
Study: 14995938

Group type: EXPERIMENTAL
Intervention: Desflurane anaesthesia supplemented with intravenous remifentanil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Desflurane anaesthesia supplemented with epidural bupivacaine
Number of subjects: 14
Study: 11746538

Group type: EXPERIMENTAL
Intervention: Central vein (CV) access
Number of subjects: 46

Group type: COMPARATOR
Intervention: Peripheral vein (PV) access
Number of subjects: 46
Study: 9541692

Group type: EXPERIMENTAL
Intervention: CD44v6-positive patients (n=219, 64.8% of the population)
Number of subjects: 338

Group type: COMPARATOR
Intervention: CD44v6-negative patients (n=119, 35.2% of the population)
Number of subjects: 338
Study: 8740308

Group type: EXPERIMENTAL
Intervention: Body contact with the mother during the first 90 minutes after birth
Number of subjects: 29

Group type: COMPARATOR
Intervention: Kept in a cot during the first 90 minutes after birth
Number of subjects: 29
Study: 2109643

Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine 500 mg (oral administration)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ibuprofen 200 mg (intravenous injection)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg (intravenous injection)
Number of subjects: 8
Study: 7350046

Group type: EXPERIMENTAL
Intervention: Pruritus
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Jaundice
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Hepatomegaly
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Pigmentation
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Xanthomas
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: GI bleeding
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Ascites
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Vertebral collapse
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Cirrhosis
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Mitochondrial antibody titer
Number of subjects: 236
Study: 31839281

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg per day, oral)
Number of subjects: 3864

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3864
Study: 30810619

Group type: EXPERIMENTAL
Intervention: Bevacizumab every month
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bevacizumab every 2 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ranibizumab every month
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 28188586

Group type: EXPERIMENTAL
Intervention: Habit formation intervention (workshop at baseline and follow-up booster phone call at week 4)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 25822707

Group type: COMPARATOR
Intervention: Ureteroscopic lithotripsy (URSL)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Retroperitoneal laparoscopic ureterolithotomy (RPLU)
Number of subjects: 232
Study: 26863558

Group type: EXPERIMENTAL
Intervention: Hypertrophy Training (HT) with Evaluative Conditioning (EC)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Hypertrophy Training (HT)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Hypertrophy Training (HT) and Power Training (PT)
Number of subjects: 231
Study: 23313202

Group type: EXPERIMENTAL
Intervention: Flexible nephroscopy during percutaneous nephrolithotomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard percutaneous nephrolithotomy using rigid nephroscopy
Number of subjects: 80
Study: 21550429

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol treatment (0.05mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study: 18461844

Group type: EXPERIMENTAL
Intervention: Brief supportive psychotherapy (BSP) training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) orientation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BSP training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prior supportive therapy training
Number of subjects: 18
Study: 16188948

Group type: EXPERIMENTAL
Intervention: SSc patients with thymus alterations
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SSc patients with disease duration ≤ 5 years
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SSc patients with serum anti-Scl70 antibodies
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SSc patients with thymus alterations post-thymectomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Controls (age- and sex-matched)
Number of subjects: 34
Study: 12686335

Group type: COMPARATOR
Intervention: Simvastatin 10 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day plus fenofibrate 200 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenofibrate 200 mg/day
Number of subjects: 0
Study: 11052841

Group type: EXPERIMENTAL
Intervention: Nadroparin (2 ml of 2500 anti-Xa-units/ml with a microporous catheter)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (no local drug delivery)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control
Number of subjects: 250
Study: 9867333

Group type: EXPERIMENTAL
Intervention: LO2A (tear substitute containing glycerine and sodium hyaluronate)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (current tear substitute)
Number of subjects: 25
Study: 7606629

Group type: EXPERIMENTAL
Intervention: Caffeine (three times daily for 6 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (three times daily for 6 days)
Number of subjects: 36
Study: 3396674

Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms or 150 micrograms)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 18
Study: 29426926

Group type: EXPERIMENTAL
Intervention: Quantum clique gossiping using local clique operations in networks of interconnected qubits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantum clique gossiping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger quantum cliques
Number of subjects: 0
Study: 28762606

Group type: EXPERIMENTAL
Intervention: D-dimer-guided warfarin therapy (low intensity adjusted to standard intensity based on D-dimer levels)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: D-dimer-guided warfarin therapy
Number of subjects: 718

Group type: COMPARATOR
Intervention: Standard intensity warfarin therapy (INR 2.5-3.5)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Low intensity warfarin therapy (INR 1.8-2.6)
Number of subjects: 718
Study: 26258147

Group type: EXPERIMENTAL
Intervention: Cinnamon tea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (without cinnamon tea)
Number of subjects: 0
Study: 23540641

Group type: EXPERIMENTAL
Intervention: Coated wires from Ortho Organizers
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Coated wires from Trianeiro
Number of subjects: 4

Group type: COMPARATOR
Intervention: Coated wires from TP Orthodontics
Number of subjects: 4

Group type: COMPARATOR
Intervention: Coated wires from Orthometric
Number of subjects: 4
Study: 21539614

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed cow's milk formula (phCMF)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional cow's milk formula (CMF)
Number of subjects: 113
Study: 18004611

Group type: EXPERIMENTAL
Intervention: Caffeine intake among women using depot medroxyprogesterone acetate (DMPA)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Caffeine intake among the general population of young women
Number of subjects: 625
Study: 16531173

Group type: EXPERIMENTAL
Intervention: Reality female condom (FC1)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Synthetic latex prototype (FC2)
Number of subjects: 276
Study: 14555563

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11094003

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 10 mL/h via a disposable infusion pump
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline at 10 mL/h via a disposable infusion pump
Number of subjects: 40
Study: 8882996

Group type: EXPERIMENTAL
Intervention: Walking 3 d.wk‐1 (N = 19)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Walking 5 d.wk‐1 (N = 17)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sedentary (Control group, N = 20)
Number of subjects: 79
Study: 8054250

Group type: EXPERIMENTAL
Intervention: 400 mg rac-ibuprofen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 800 mg rac-ibuprofen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3047100

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg nightly for 5 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31994303

Group type: EXPERIMENTAL
Intervention: 270 mg ferrous sulfate twice a day (total elemental iron dose: 160 mg / day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 270 mg ferrous sulfate once a day (total elemental iron dose: 80 mg / day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 270 mg ferrous sulfate every other day (total elemental iron dose: 80 mg / every other day)
Number of subjects: 0
Study: 27048306

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 411

Group type: COMPARATOR
Intervention: Stress Testing
Number of subjects: 411
Study: 25922062

Group type: EXPERIMENTAL
Intervention: Mito-FLAG with Ara-C as bolus (1000 mg/m(2) over 1 h, every 12 h, days 1-5)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Mito-FLAG with Ara-C as continuous infusion (150 mg/m(2) over 24 h, days 1-5)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Mito-FLAG with Ara-C as bolus
Number of subjects: 252

Group type: COMPARATOR
Intervention: Mito-FLAG with Ara-C as continuous infusion
Number of subjects: 252
Study: 23827771

Group type: EXPERIMENTAL
Intervention: Betamethasone + Essex® cream
Number of subjects: 104

Group type: COMPARATOR
Intervention: Essex® cream
Number of subjects: 104

Group type: COMPARATOR
Intervention: Canoderm® cream
Number of subjects: 104
Study: 21062464

Group type: EXPERIMENTAL
Intervention: NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype)
Number of subjects: 630

Group type: COMPARATOR
Intervention: NRT oral dose tailored by nicotine dependence questionnaire score (phenotype)
Number of subjects: 630
Study: 18476606

Group type: EXPERIMENTAL
Intervention: BCG-PSN 1.0 mg twice a week for two months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intranasal azelastine twice a day as needed
Number of subjects: 60
Study: 17182361

Group type: EXPERIMENTAL
Intervention: Iscador therapy (mistletoe preparation)
Number of subjects: 197
Study: 14658986

Group type: EXPERIMENTAL
Intervention: Long-term pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy (alone or combined with medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10714729

Group type: EXPERIMENTAL
Intervention: Methadone Maintenance Therapy (MMT)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Detoxification
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 179
Study: 8704662

Group type: EXPERIMENTAL
Intervention: Individualized planned care for patients and regular clinical systematic supervision for nurses on the experimental ward (EW)
Number of subjects: 107

Group type: COMPARATOR
Intervention: No changes made on the control ward (CW)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Surviving patients in the experimental ward (EW)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Surviving patients in the control ward (CW)
Number of subjects: 107
Study: 1431251

Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccines
Number of subjects: 646
Study: 6697786

Group type: EXPERIMENTAL
Intervention: Inhaled glycopyrrolate (1.3 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atropine (2.6 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31525242

Group type: EXPERIMENTAL
Intervention: Mothers with at least secondary level of formal education
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Mothers whose first pregnancy occurred between the ages of 20‐24 years
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Mothers who had completed at least four ANC visits
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Mothers who had completed three PNC visits
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Mothers whose nearest health facility was less than one hour walking distance (30‐59 minutes)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Mothers whose household monthly income was more than $100
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Mothers with adequate newborn care knowledge
Number of subjects: 302
Study: 29409494

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine Zengru Gao
Number of subjects: 588

Group type: COMPARATOR
Intervention: Control group (no Zengru Gao)
Number of subjects: 588
Study: 27045034

Group type: EXPERIMENTAL
Intervention: Fenretinide (oral retinoid) for 2 years
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Baseline VEGF levels in the top quintile (≥350 pg/mL)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: DNA aneuploidy in bladder washing
Number of subjects: 99
Study: 24578135

Group type: EXPERIMENTAL
Intervention: Neutralization of Dkk1 using a monoclonal antibody after renal injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphate binder therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Dkk1 antibody and phosphate binder therapy
Number of subjects: 0
Study: 22925537

Group type: EXPERIMENTAL
Intervention: 40,000 IU vitamin D (cholecalciferol) per week
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 20,000 IU vitamin D per week
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study: 20205105

Group type: COMPARATOR
Intervention: (131)I and thiamazole
Number of subjects: 200

Group type: COMPARATOR
Intervention: (131)I and lithium carbonate
Number of subjects: 200

Group type: COMPARATOR
Intervention: (131)I only (150-200 Gy)
Number of subjects: 200

Group type: COMPARATOR
Intervention: (131)I and prednisone
Number of subjects: 200

Group type: COMPARATOR
Intervention: (131)I only (250-350 Gy)
Number of subjects: 200
Study: 17396552

Group type: EXPERIMENTAL
Intervention: PDA technology (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Textbook (control group)
Number of subjects: 0
Study: 16215448

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Medical management plus psychological intervention
Number of subjects: 220
Study: 12208481

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Pravastatin (CC genotype)
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Pravastatin (CT genotype)
Number of subjects: 1431

Group type: COMPARATOR
Intervention: Placebo (reference group)
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Baseline FXIIa levels
Number of subjects: 1431
Study: 10206198

Group type: EXPERIMENTAL
Intervention: Ovulation induction (clomiphene, hMG)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Expectant management (no further treatment)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 128
Study: 7500752

Group type: EXPERIMENTAL
Intervention: High-dose traction
Number of subjects: 151

Group type: COMPARATOR
Intervention: Sham traction
Number of subjects: 151
Study: 2217010

Group type: EXPERIMENTAL
Intervention: Combination of thiopentone and etomidate (5:1 ratio)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of thiopentone and etomidate (13:1 ratio)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of thiopentone and etomidate (25:1 ratio)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etomidate alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiopentone alone
Number of subjects: 0
Study: 6994960

Group type: EXPERIMENTAL
Intervention: Phenytoin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what treatment was used)
Number of subjects: 0
Study: 31220775

Group type: EXPERIMENTAL
Intervention: S-ICD implantation with DFT
Number of subjects: 965

Group type: COMPARATOR
Intervention: S-ICD implantation without DFT (with PRAETORIAN score evaluation)
Number of subjects: 965
Study: 27801706

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 21711

Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D (Ca/D)
Number of subjects: 21711

Group type: EXPERIMENTAL
Intervention: Hormone Therapy + Calcium + Vitamin D (HT + Ca/D)
Number of subjects: 21711
Study: 25874723

Group type: COMPARATOR
Intervention: HIV-DNA vaccine containing plasmids expressing HIV-1 gp160 subtypes A, B, C, Rev B, Gag A, B and RTmut B, followed by recombinant HIV-MVA boost expressing CRF01_AE HIV-1 Env subtype E and Gag-Pol subtype A.
Number of subjects: 0
Study: 23329203

Group type: EXPERIMENTAL
Intervention: Perturbations at varying bandwidths (0.3 Hz to 8.0 Hz) with eyes open
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perturbations at varying bandwidths (0.3 Hz to 8.0 Hz) with eyes closed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of reflexes with eyes open vs. eyes closed
Number of subjects: 0
Study: 20650570

Group type: EXPERIMENTAL
Intervention: Laboratory stress (LS; public speaking)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Simulated emergency situation (SIM; myocardial ischemia and ventricular fibrillation)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 34
Study: 19622191

Group type: EXPERIMENTAL
Intervention: Fermented milk (FM) containing Bifidobacterium lactis DN-173 010 and yoghurt strains
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control non-fermented dairy product
Number of subjects: 197
Study: 16418018

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg 1 hour before surgery, then 200 mg every 12 hours for the first 5 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15590524

Group type: EXPERIMENTAL
Intervention: Terminal tarsal rotation (n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tarsal rotation with tarso‐conjunctival advancement (n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Anterior lamellar repositioning with lid margin split and wedge resection of tarsus (n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: All procedures
Number of subjects: 90
Study: 11668377

Group type: EXPERIMENTAL
Intervention: Cervical block anesthesia
Number of subjects: 401

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 401
Study: 9211578

Group type: EXPERIMENTAL
Intervention: Thiamine (5 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (5 g lactose)
Number of subjects: 8
Study: 8433254

Group type: EXPERIMENTAL
Intervention: Tetracycline HCl 50 mg/ml
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tetracycline HCl 10 mg/ml
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (0.9% sterile saline)
Number of subjects: 50
Study: 2954215

Group type: EXPERIMENTAL
Intervention: Low-frequency electrical stimulation
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Exercises
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Medium-high-frequency electrical stimulation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 28892591

Group type: EXPERIMENTAL
Intervention: Etanercept 10 mg once-weekly
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice-weekly
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Etanercept 10 mg twice-weekly
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg every 2 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once-weekly
Number of subjects: 61
Study: 27660305

Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided ultrafiltration prescription policy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 79
Study: 25068411

Group type: EXPERIMENTAL
Intervention: Lidocaine 3 mg/kg plus ketamine 50 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine 3 mg/kg
Number of subjects: 40
Study: 22520536

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Ezetimibe 10 mg
Number of subjects: 1421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Left ventricular mass index
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: New-onset AF
Number of subjects: 1421